DLA Piper advised Brookline Capital Acquisition Corp., a special purpose acquisition company, in the closing of its business combination with Apexigen, Inc., a clinical-stage biopharmaceutical company. The combined, publicly traded company will operate under the name Apexigen, and its common stock commenced trading on the Nasdaq Capital Market on August 1, 2022 under the ticker symbol […]
The post DLA Piper advises Brookline Capital Acquisition Corp. in the closing of its business combination with Apexigen, Inc. appeared first on Legal Desire.